Shinobu Kitazume
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shinobu Kitazume has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
Kazuto Takahashi
Department of Clinical Laboratory Sciences, Graduate School of Health Sciences, Fukushima Medical University, Fukushima 960-8516, Japan
8 shared publicationsKenichiro Nagai
Department of Neurosurgery, Fukushima Medical University , Fukushima
5 shared publicationsYasushi Kawaguchi
Department of Infectious Disease Control, The Institute of Medical Science, The University of Tokyo , Tokyo
5 shared publicationsYuko Hashimoto
Department of Diagnostic Pathology, Fukushima Medical University, Fukushima 960-1295, Japan
5 shared publicationsYuriko Tachida
Glycan and Life Systems Integration Center (GaLSIC), Soka University, Hachioji, Japan
5 shared publicationsHideaki Suzuki
Department of Clinical Laboratory Sciences, Graduate School of Health Sciences, Fukushima Medical University , Fukushima
4 shared publications
Latest Publications
- 1 July 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1870 (10) , 130975
GALNT6 localization is associated with gland-forming architecture and morphological differentiation in luminal A breast cancer
- 1 July 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1870 (10) , 130975
GALNT6 localization is associated with gland-forming architecture and morphological differentiation in luminal A breast cancer
- 1 May 2026
- Published by Springer Nature
- p. 247-250
Alzheimer’s Disease (AD) (2)
- 1 April 2026
- Published by Springer Nature
- Vol. 1491, 33-42
Unique Expression and Glycosylation of Amyloid Precursor Protein in Alzheimer’s Disease
Accumulation of amyloid β (Aβ) peptide in the brain is a characteristic pathological feature of Alzheimer's disease that occurs several decades before the onset of symptoms. Aβ is produced from the membrane-bound amyloid β precursor protein (APP) by β-secretase 1 (BACE1) and γ-secretase-mediated proteolytic cleavage. Alternatively, ADAM10/17 α-secretase and γ-secretase cleavage does not generate Aβ. Accumulating evidence indicates that intracellular trafficking of APP to each secretase determines the level of Aβ production. In this chapter, we summarize how glycosylation affects the Aβ production, possibly by modulating the intracellular localization of APP and its secretases.
- 1 April 2026
- Published by Springer Nature
- Vol. 1491, 33-42
Unique Expression and Glycosylation of Amyloid Precursor Protein in Alzheimer’s Disease
Accumulation of amyloid β (Aβ) peptide in the brain is a characteristic pathological feature of Alzheimer's disease that occurs several decades before the onset of symptoms. Aβ is produced from the membrane-bound amyloid β precursor protein (APP) by β-secretase 1 (BACE1) and γ-secretase-mediated proteolytic cleavage. Alternatively, ADAM10/17 α-secretase and γ-secretase cleavage does not generate Aβ. Accumulating evidence indicates that intracellular trafficking of APP to each secretase determines the level of Aβ production. In this chapter, we summarize how glycosylation affects the Aβ production, possibly by modulating the intracellular localization of APP and its secretases.
- Open Access
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Cerebrospinal fluid soluble protein tyrosine phosphatase receptor type Z detected with human natural killer-1 antibody as a practical biomarker for glioma diagnosis
Background: A major challenge in managing gliomas is the lack of reliable and clinically applicable biomarkers. Imaging alone is often insufficient to distinguish gliomas from primary central nervous system lymphoma (PCNSL), necessitating invasive biopsy. Soluble protein tyrosine phosphatase receptor type Z (sPTPRZ) in cerebrospinal fluid (CSF) has recently emerged as a promising candidate. We evaluated the diagnostic utility of CSF sPTPRZ in differentiating gliomas from PCNSL. Methods: We developed an anti-HNK-1 antibody-based ELISA for CSF sPTPRZ and analyzed 51 glioma, 15 PCNSL, and 20 control patients. Complementary assays included western blotting, immunohistochemistry, qPCR. sPTPRZ immunopurified from glioma CSF was used to determine HNK-1 epitope sites. RNA-seq data from the C-CAT database were used to identify PTPRZ gene fusions. Results: CSF sPTPRZ levels were significantly elevated in glioma patients compared with both controls and PCNSL, demonstrating robust discrimination between these entities (AUC = 0.910 vs controls; AUC = 0.805 vs PCNSL; P = .0010). PTPRZ expression was absent in PCNSL, consistent with low CSF sPTPRZ. Mass spectrometry localized the HNK-1 epitope to exon 12 of PTPRZ-long, absent in PTPRZ-MET fusion variants (2% of gliomas). These insights may explain low sPTPRZ levels in a subset of gliomas. Conclusion: CSF sPTPRZ detection with anti-HNK-1 antibody is a minimally invasive biomarker for glioma. It significantly improves diagnostic discrimination from PCNSL, and provides a molecular rationale for biomarker-negative glioma subsets with PTPRZ-MET fusions.
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Open AccessCerebrospinal fluid soluble protein tyrosine phosphatase receptor type Z detected with human natural killer-1 antibody as a practical biomarker for glioma diagnosis
Background: A major challenge in managing gliomas is the lack of reliable and clinically applicable biomarkers. Imaging alone is often insufficient to distinguish gliomas from primary central nervous system lymphoma (PCNSL), necessitating invasive biopsy. Soluble protein tyrosine phosphatase receptor type Z (sPTPRZ) in cerebrospinal fluid (CSF) has recently emerged as a promising candidate. We evaluated the diagnostic utility of CSF sPTPRZ in differentiating gliomas from PCNSL. Methods: We developed an anti-HNK-1 antibody-based ELISA for CSF sPTPRZ and analyzed 51 glioma, 15 PCNSL, and 20 control patients. Complementary assays included western blotting, immunohistochemistry, qPCR. sPTPRZ immunopurified from glioma CSF was used to determine HNK-1 epitope sites. RNA-seq data from the C-CAT database were used to identify PTPRZ gene fusions. Results: CSF sPTPRZ levels were significantly elevated in glioma patients compared with both controls and PCNSL, demonstrating robust discrimination between these entities (AUC = 0.910 vs controls; AUC = 0.805 vs PCNSL; P = .0010). PTPRZ expression was absent in PCNSL, consistent with low CSF sPTPRZ. Mass spectrometry localized the HNK-1 epitope to exon 12 of PTPRZ-long, absent in PTPRZ-MET fusion variants (2% of gliomas). These insights may explain low sPTPRZ levels in a subset of gliomas. Conclusion: CSF sPTPRZ detection with anti-HNK-1 antibody is a minimally invasive biomarker for glioma. It significantly improves diagnostic discrimination from PCNSL, and provides a molecular rationale for biomarker-negative glioma subsets with PTPRZ-MET fusions.
- Open Access
- 6 November 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 791, 152925
Analysis of PTPRZ expression in glioma and schwannoma — PTPRZ-long is highly expressed and shed in glioma —
- 6 November 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 791, 152925
Open AccessAnalysis of PTPRZ expression in glioma and schwannoma — PTPRZ-long is highly expressed and shed in glioma —
- Open Access
HNK-1 Antibody-Based ELISA for Soluble PTPRZ: A Practical Cerebrospinal Fluid Biomarker for Glioma
Reliable fluid biomarkers for glioma remain elusive, complicating diagnosis and differentiation from primary central nervous system lymphoma (PCNSL). We evaluated soluble protein tyrosine phosphatase receptor type Z (sPTPRZ) in cerebrospinal fluid (CSF) using an anti-HNK-1 antibody-based ELISA. CSF sPTPRZ levels were significantly elevated in glioma patients compared with controls (AUC = 0.910) and moderately distinguished gliomas from PCNSL (AUC = 0.805). Immunohistochemistry and qPCR confirmed lack of PTPRZ expression in PCNSL, while epitope mapping localized the HNK-1 modification site to exon 12 of the long isoform. RNA-seq of the C-CAT database revealed PTPRZ-MET fusions in 2% of gliomas, all lacking the HNK-1 epitope, consistent with low CSF sPTPRZ in a subset of tumors. These findings establish CSF sPTPRZ detection with anti-HNK-1 antibody as a minimally invasive and robust biomarker for glioma, supporting improved diagnostic accuracy and aiding clinical decision-making in neuro-oncology.
Open AccessHNK-1 Antibody-Based ELISA for Soluble PTPRZ: A Practical Cerebrospinal Fluid Biomarker for Glioma
Reliable fluid biomarkers for glioma remain elusive, complicating diagnosis and differentiation from primary central nervous system lymphoma (PCNSL). We evaluated soluble protein tyrosine phosphatase receptor type Z (sPTPRZ) in cerebrospinal fluid (CSF) using an anti-HNK-1 antibody-based ELISA. CSF sPTPRZ levels were significantly elevated in glioma patients compared with controls (AUC = 0.910) and moderately distinguished gliomas from PCNSL (AUC = 0.805). Immunohistochemistry and qPCR confirmed lack of PTPRZ expression in PCNSL, while epitope mapping localized the HNK-1 modification site to exon 12 of the long isoform. RNA-seq of the C-CAT database revealed PTPRZ-MET fusions in 2% of gliomas, all lacking the HNK-1 epitope, consistent with low CSF sPTPRZ in a subset of tumors. These findings establish CSF sPTPRZ detection with anti-HNK-1 antibody as a minimally invasive and robust biomarker for glioma, supporting improved diagnostic accuracy and aiding clinical decision-making in neuro-oncology.
- Open Access
- 3 August 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (9) , 105128
Brain-specific glycosylation enzyme GnT-IX maintains levels of protein tyrosine phosphatase receptor PTPRZ, thereby mediating glioma growth
- 3 August 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (9) , 105128
Open AccessBrain-specific glycosylation enzyme GnT-IX maintains levels of protein tyrosine phosphatase receptor PTPRZ, thereby mediating glioma growth
- Open Access
- 9 June 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (7) , 104905
O-GalNAc glycosylation determines intracellular trafficking of APP and Aβ production
- 9 June 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (7) , 104905
Open AccessO-GalNAc glycosylation determines intracellular trafficking of APP and Aβ production
- 16 April 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 166 (3) , 547-559
Brain‐specific glycosylation of protein tyrosine phosphatase receptor type Z (PTPRZ) marks a demyelination‐associated astrocyte subtype
Astrocytes are the most abundant glial cell type in the brain, where they participate in various homeostatic functions. Transcriptomically, diverse astrocyte subpopulations play distinct roles during development and disease progression. However, the biochemical identification of astrocyte subtypes, especially by membrane surface protein glycosylation, remains poorly investigated. Protein tyrosine phosphatase receptor type zeta (PTPRZ) is a highly expressed membrane protein in CNS glia cells that can be modified with diverse glycosylation, including the unique HNK‐1 capped O‐mannosyl (O‐Man) core M2 glycan mediated by brain‐specific branching enzyme GnT‐IX. Although PTPRZ modified with HNK‐1 capped O‐Man glycans (HNK‐1‐O‐Man+ PTPRZ) is increased in reactive astrocytes of demyelination model mice, whether such astrocytes emerge in a broad range of disease‐associated conditions or are limited to conditions associated with demyelination remains unclear. Here, we show that HNK‐1‐O‐Man+ PTPRZ localizes in hypertrophic astrocytes of damaged brain areas in patients with multiple sclerosis. Furthermore, we show that astrocytes expressing HNK‐1‐O‐Man+ PTPRZ are present in two demyelination mouse models (cuprizone‐fed mice and a vanishing white matter disease model), while traumatic brain injury does not induce glycosylation. Administration of cuprizone to Aldh1l1‐eGFP and Olig2KICreER/+;Rosa26eGFP mice revealed that cells expressing HNK‐1‐O‐Man+ PTPRZ are derived from cells in the astrocyte lineage. Notably, GnT‐IX but not PTPRZ mRNA was up‐regulated in astrocytes isolated from the corpus callosum of cuprizone model mice. These results suggest that the unique PTPRZ glycosylation plays a key role in the patterning of demyelination‐associated astrocytes. image
- 16 April 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 166 (3) , 547-559
Brain‐specific glycosylation of protein tyrosine phosphatase receptor type Z (PTPRZ) marks a demyelination‐associated astrocyte subtype
Astrocytes are the most abundant glial cell type in the brain, where they participate in various homeostatic functions. Transcriptomically, diverse astrocyte subpopulations play distinct roles during development and disease progression. However, the biochemical identification of astrocyte subtypes, especially by membrane surface protein glycosylation, remains poorly investigated. Protein tyrosine phosphatase receptor type zeta (PTPRZ) is a highly expressed membrane protein in CNS glia cells that can be modified with diverse glycosylation, including the unique HNK‐1 capped O‐mannosyl (O‐Man) core M2 glycan mediated by brain‐specific branching enzyme GnT‐IX. Although PTPRZ modified with HNK‐1 capped O‐Man glycans (HNK‐1‐O‐Man+ PTPRZ) is increased in reactive astrocytes of demyelination model mice, whether such astrocytes emerge in a broad range of disease‐associated conditions or are limited to conditions associated with demyelination remains unclear. Here, we show that HNK‐1‐O‐Man+ PTPRZ localizes in hypertrophic astrocytes of damaged brain areas in patients with multiple sclerosis. Furthermore, we show that astrocytes expressing HNK‐1‐O‐Man+ PTPRZ are present in two demyelination mouse models (cuprizone‐fed mice and a vanishing white matter disease model), while traumatic brain injury does not induce glycosylation. Administration of cuprizone to Aldh1l1‐eGFP and Olig2KICreER/+;Rosa26eGFP mice revealed that cells expressing HNK‐1‐O‐Man+ PTPRZ are derived from cells in the astrocyte lineage. Notably, GnT‐IX but not PTPRZ mRNA was up‐regulated in astrocytes isolated from the corpus callosum of cuprizone model mice. These results suggest that the unique PTPRZ glycosylation plays a key role in the patterning of demyelination‐associated astrocytes. image
- Open Access
Non-classical glycosylation determines intracellular trafficking of APP and Aβ production
A primary pathology of Alzheimer’s disease (AD) is Aβ deposition in brain parenchyma and blood vessels, the latter being called cerebral amyloid angiopathy (CAA). Parenchymal amyloid plaques presumably originate from neuronal Aβ precursor protein (APP), but vascular amyloid deposits’ origins remain unclear. Endothelial APP expression in APP-knock-in mice was recently shown to expand CAA pathology, highlighting endothelial APP’s importance. Furthermore, two types of endothelial APP—with and without O-glycans—have been biochemically identified, but only the former is cleaved for Aβ production, indicating the critical relationship between APP O-glycosylation and processing. Here, we analyzed APP glycosylation and its intracellular trafficking in neurons and endothelial cells. Although protein glycosylation is generally believed to precede cell surface trafficking, which was true for neuronal APP, we unexpectedly observed that APP lacking O-glycans is externalized to the endothelial cell surface and transported back to the Golgi apparatus, where it then acquires O-glycans. Knockdown of genes encoding enzymes initiating APP O-glycosylation significantly reduced Αβ production, suggesting this non-classical glycosylation pathway contributes to CAA pathology and is a novel therapeutic target.
Open AccessNon-classical glycosylation determines intracellular trafficking of APP and Aβ production
A primary pathology of Alzheimer’s disease (AD) is Aβ deposition in brain parenchyma and blood vessels, the latter being called cerebral amyloid angiopathy (CAA). Parenchymal amyloid plaques presumably originate from neuronal Aβ precursor protein (APP), but vascular amyloid deposits’ origins remain unclear. Endothelial APP expression in APP-knock-in mice was recently shown to expand CAA pathology, highlighting endothelial APP’s importance. Furthermore, two types of endothelial APP—with and without O-glycans—have been biochemically identified, but only the former is cleaved for Aβ production, indicating the critical relationship between APP O-glycosylation and processing. Here, we analyzed APP glycosylation and its intracellular trafficking in neurons and endothelial cells. Although protein glycosylation is generally believed to precede cell surface trafficking, which was true for neuronal APP, we unexpectedly observed that APP lacking O-glycans is externalized to the endothelial cell surface and transported back to the Golgi apparatus, where it then acquires O-glycans. Knockdown of genes encoding enzymes initiating APP O-glycosylation significantly reduced Αβ production, suggesting this non-classical glycosylation pathway contributes to CAA pathology and is a novel therapeutic target.